Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ocugen, Inc. Director's Dealing 2019

Dec 16, 2019

32915_dirs_2019-12-16_df4cd23e-c870-495f-898c-e1146740d712.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Ocugen, Inc. (OCGN)
CIK: 0001372299
Period of Report: 2019-09-27

Reporting Person: Tammara Vijay (Vice President)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Options (right to buy) $.46 2024-09-18 Common Stock (18217) Direct
Stock Options (right to buy) $2.94 2026-04-26 Common Stock (7191) Direct
Stock Options (right to buy) $7.56 2027-08-17 Common Stock (7191) Direct
Stock Options (right to buy) $7.56 2027-12-15 Common Stock (7191) Direct
Stock Options (right to buy) $12.18 2028-08-13 Common Stock (2397) Direct
Stock Options (right to buy) $13.52 2028-12-07 Common Stock (9588) Direct

Footnotes

F1: 100% of the Stock Options became exercisable immediately.

F2: 4,794 Stock Options became exercisable immediately, and the remaining 2,397 Stock Options will become exercisable on August 17, 2020, subject to continued employment with Ocugen, Inc. (the "Company").

F3: 2,397 Stock Options became exercisable immediately, and the remaining 4,794 Stock Options will become exercisable 50% each on December 15, 2019 and December 14, 2020, subject to continued employment with Company through the applicable vesting date.

F4: 799 Stock Options became exercisable immediately, and the remaining 1,598 Stock Options will become exercisable 50% each on July 23, 2020 and July 22, 2021, subject to continued employment with Company through the applicable vesting date.

F5: The Stock Options will become exercisable 1/3 each on December 7, 2019, December 7, 2020 and December 6, 2021, subject to continued employment with Company through the applicable vesting date.